FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

  • 📰 Reuters
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 97%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

U.S. health regulators on Friday approved expanding the heart benefit claims Ama...

- U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

Vascepa, a highly purified form of omega-3 fatty acid, won U.S. approval in 2012 to lower high triglycerides - a type of blood fat that can increase the risk of heart disease. Vascepa has been heralded as a potential game changer in the cardiovascular disease market by Wall Street analysts. Vascepa has been highlighted as a cost-effective add-on to statins by the Institute for Clinical and Economic Review. The therapy’s annual cost based on list price of around $3,600 is much lower than the non-profit group’s recommended value-based price range of $6,300 to $9,200.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Cool

Did the FDA have to steal Sega’s font

Grandma’s cod liver oil ?

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines